Anti-IL-5 biologics and antifibrotic agents offer a phenotype-adapted framework for fibrotic chronic eosinophilic pneumonia
Background
While chronic eosinophilic pneumonia (CEP) is typically responsive to systemic glucocorticoids, patients frequently experience relapses and treatment-related toxicity. Monoclonal antibodies targeting the interleukin-5 (IL-5) pathway have emerged as glucocorticoid-sparing options. However, a significant proportion of patients develop progressive fibrotic changes, challenging the traditional view of CEP as a fully reversible condition and highlighting a critical gap in managing this fibrotic phenotype.
Study Design
This narrative review summarized current clinical evidence on anti-IL-5/IL-5 receptor subunit α biologicals in chronic eosinophilic pneumonia. Researchers examined the emerging phenotype of fibrotic CEP and discussed the mechanistic links between eosinophilic inflammation and pulmonary fibrosis. The review also synthesized experimental and clinical data implicating eosinophils, type 2 cytokines, epithelial alarmins, and extracellular traps in fibroblast activation and extracellular matrix deposition.
Results
The review established a biological rationale for a continuum from eosinophilic inflammation to irreversible lung remodeling, driven by eosinophils, type 2 cytokines, epithelial alarmins, and extracellular traps that activate fibroblasts and promote extracellular matrix deposition. While anti-IL-5-targeted therapies are effective for inflammation, available data on their use in established fibrotic disease are limited, with no prospective studies specifically addressing this patient population. Conversely, antifibrotic agents like nintedanib have demonstrated efficacy in progressive fibrosing interstitial lung diseases, but have been rarely studied in eosinophilic lung disorders. The authors propose a phenotype-adapted therapeutic framework: > Sustained control of eosinophilic inflammation aims to prevent fibrotic progression in early disease, while antifibrotic therapy may be considered in patients with established or progressive fibrosis.
Key Findings
- Chronic eosinophilic pneumonia can progress to irreversible fibrosis, challenging its traditional view as a fully reversible condition.
- Eosinophils, type 2 cytokines, epithelial alarmins, and extracellular traps mechanistically link inflammation to pulmonary fibrosis.
- Anti-IL-5 pathway biologics are effective for inflammation but have limited data in fibrotic chronic eosinophilic pneumonia.
- Antifibrotic agents like nintedanib are effective in other fibrosing lung diseases but are understudied in eosinophilic disorders.
- A phenotype-adapted framework is proposed: anti-inflammatory for early disease, antifibrotic therapy for established fibrosis.
Why It Matters
This proposed phenotype-adapted therapeutic framework offers a crucial shift in managing fibrotic chronic eosinophilic pneumonia, moving beyond a purely anti-inflammatory strategy. It suggests a personalized approach that could significantly improve long-term outcomes by preventing irreversible lung remodeling and reducing reliance on systemic glucocorticoids. Clinicians should consider integrating anti-inflammatory strategies (e.g., anti-IL-5 biologics) for early disease and antifibrotic agents (e.g., nintedanib) for established or progressive fibrosis. This framework provides a rationale for combining different therapeutic classes based on disease stage, potentially leading to more effective and durable treatment protocols.
chronic eosinophilic pneumonia
pulmonary fibrosis
il-5
biologics
nintedanib
inflammation